mapk

MBP MAPK Substrate acetate can be used as an exogenous substrate for MAPK.

MBP (MAPK) Substrate is an exogenous substrate utilized for MAPK.

Ziptide serves as a substrate for various kinases, including MAPK protein kinase 2 (MAPKAPK2, Km= 5 μM), MAPKAPK3 (Km= 30 μM), PARK (Km= 40 μM), checkpoint kinase 1 (Chk1, Km= 5 μM), AMP-activated protein kinase (AMPK, Km= 75 μM), and calcium/calmodulin-dependent protein kinase II (CamKII, Km= 300 μM).

SN50 is a cell permeable NF-κB translocation inhibitor.

MMI-0100, a cell-permeant peptide inhibitor of mitogen-activated protein kinase activated protein kinase II (MK2), effectively reduces intimal hyperplasia ex vivo and in vivo. It specifically suppresses IL-6 expression while not affecting IL-8 expression and mitigates fibrotic processes, including vein graft disease [1].

MK2-IN-5, a pseudosubstrate of Mk2 with an inhibition constant (K_i) of 8 μM, selectively targets the protein interaction domain of the MAPK pathway and inhibits the phosphorylation of HSP25 and HSP27 [1] [2] [3].

Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. It indirectly decreases osteoclast differentiation by reducing the RANKL/OPG ratio and directly increases osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways, thereby inducing bone formation via Runx2.

Nisin Z has anti-inflammatory activity and reduces pro-inflammatory cytokine release by inhibiting activation of the ERK1/2 and p38 mitogen-activated protein kinase (MAPK) signaling pathways, attenuating lipopolysaccharide-induced mastitis through inhibition of the ERK1/2 and p38 mitogen-activated protein kinase signaling pathways.

Cyclosporin H (CsH), a specific inhibitor of FPR1, inhibited lung inflammation in the ALI models. CsH significantly attenuated MTDs or NFP-induced inflammatory lung injury and activation of MAPK and AKT pathways. Cyclosporin H is a viral transduction enha

OVA-E1 peptide TFA activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.

Apelin-12 acetate possesses a high affinity to orphan receptor APJ receptor. Apelin-12 acetate inhibits the JNK and p38 MAPK signaling pathway of the apoptosis-related MAPKs family, thus offering protection to neurons.

EGF-R (661-681) T669 Peptide, a substrate of MAPK, facilitates the measurement of MAPK catalytic activity [1].

Ziptide, a peptide substrate, is recognized by several serine/threonine protein kinases, such as MAPK activated protein kinase 2 (MAPKAPK2), MAPKAPK3, MAPKAPK5, checkpoint kinase 1 (Chk1), AMP-activated protein kinase (AMPK), and calcium/calmodulin-dependent protein kinase II (CamKII). It serves as a tool in evaluating CamKII activity for the development of inhibitors.

Ac2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.

Ac2-26 acetate is an active N-terminal peptide of annexin A1(AnxA1). Ac2-26 acetate decreases AnxA1 protein expression and inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue. Ac2-26 acetate attenuates ischemia-reperfusion-induced acute lung injury.

Amylin (AMY3) receptor antagonist. Inhibits andrenomedulin-stimulated cAMP production in vitro. Protects against oligomeric Aβ-induced increase in intracellular Ca2+, activation of PKA, MAPK, Akt and cFOS and cell death in neuronal cell culture. Blocks el

KRas/son of sevenless 1 (SOS1) interaction inhibitor. Binds within nucleotide binding pocket of KRas (Kd values are 106 - 176 nM for wild type KRas and various KRas mutants). Inhibits nucleotide binding to KRas in a concentration dependent manner. Display

This Mitogen-activated protein kinase (MAP kinase) fragment has a peptide sequence of Lys-Tyr-Ile-His-Ser-Ala-Asn-Val-Leu. The MAP kinases are serine/threonine-specific protein kinases belonging to the CMGC (CDK/MAPK/GSK3/CLK) kinase group.

PAR3 (1-6) is a synthetic peptide agonist of Protease-Activated Receptor 1 (PAR1), corresponding to residues 1-6 of the extracellular tethered ligand sequence from human PAR3 and residues 39-44 of the full-length human sequence. PAR3 (1-6) activates the p42/44 MAPK signaling pathway in fibroblasts expressing PAR1 but not PAR3. This activation can be inhibited by the PAR1 antagonist RWJ 56110.1.